Logo image of HALO

HALOZYME THERAPEUTICS INC (HALO) Stock Fundamental Analysis

NASDAQ:HALO - Nasdaq - US40637H1095 - Common Stock - Currency: USD

58.79  -0.03 (-0.05%)

After market: 59 +0.21 (+0.36%)

Fundamental Rating

8

Overall HALO gets a fundamental rating of 8 out of 10. We evaluated HALO against 568 industry peers in the Biotechnology industry. HALO gets an excellent profitability rating and is at the same time showing great financial health properties. HALO has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! These ratings would make HALO suitable for value and growth and quality investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

In the past year HALO was profitable.
HALO had a positive operating cash flow in the past year.
HALO had positive earnings in each of the past 5 years.
Each year in the past 5 years HALO had a positive operating cash flow.
HALO Yearly Net Income VS EBIT VS OCF VS FCFHALO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

1.2 Ratios

HALO's Return On Assets of 21.52% is amongst the best of the industry. HALO outperforms 98.94% of its industry peers.
HALO has a better Return On Equity (122.06%) than 99.47% of its industry peers.
Looking at the Return On Invested Capital, with a value of 23.00%, HALO belongs to the top of the industry, outperforming 99.12% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for HALO is above the industry average of 14.25%.
The 3 year average ROIC (17.81%) for HALO is below the current ROIC(23.00%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 21.52%
ROE 122.06%
ROIC 23%
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
HALO Yearly ROA, ROE, ROICHALO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 200 300

1.3 Margins

HALO has a Profit Margin of 43.74%. This is amongst the best in the industry. HALO outperforms 99.12% of its industry peers.
HALO's Profit Margin has declined in the last couple of years.
HALO has a better Operating Margin (54.32%) than 99.82% of its industry peers.
HALO's Operating Margin has declined in the last couple of years.
HALO has a Gross Margin of 84.30%. This is amongst the best in the industry. HALO outperforms 86.97% of its industry peers.
HALO's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 54.32%
PM (TTM) 43.74%
GM 84.3%
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
HALO Yearly Profit, Operating, Gross MarginsHALO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

8

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so HALO is creating value.
HALO has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, HALO has less shares outstanding
HALO has a better debt/assets ratio than last year.
HALO Yearly Shares OutstandingHALO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
HALO Yearly Total Debt VS Total AssetsHALO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

An Altman-Z score of 4.73 indicates that HALO is not in any danger for bankruptcy at the moment.
HALO has a better Altman-Z score (4.73) than 81.51% of its industry peers.
The Debt to FCF ratio of HALO is 3.21, which is a good value as it means it would take HALO, 3.21 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of HALO (3.21) is better than 94.01% of its industry peers.
HALO has a Debt/Equity ratio of 4.14. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of HALO (4.14) is worse than 83.27% of its industry peers.
Industry RankSector Rank
Debt/Equity 4.14
Debt/FCF 3.21
Altman-Z 4.73
ROIC/WACC2.43
WACC9.48%
HALO Yearly LT Debt VS Equity VS FCFHALO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

HALO has a Current Ratio of 7.80. This indicates that HALO is financially healthy and has no problem in meeting its short term obligations.
HALO has a better Current ratio (7.80) than 73.42% of its industry peers.
A Quick Ratio of 6.78 indicates that HALO has no problem at all paying its short term obligations.
HALO has a Quick ratio of 6.78. This is in the better half of the industry: HALO outperforms 67.96% of its industry peers.
Industry RankSector Rank
Current Ratio 7.8
Quick Ratio 6.78
HALO Yearly Current Assets VS Current LiabilitesHALO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

8

3. Growth

3.1 Past

HALO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 52.16%, which is quite impressive.
HALO shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 30.12% yearly.
Looking at the last year, HALO shows a very strong growth in Revenue. The Revenue has grown by 22.46%.
Measured over the past years, HALO shows a very strong growth in Revenue. The Revenue has been growing by 38.95% on average per year.
EPS 1Y (TTM)52.16%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%53.66%
Revenue 1Y (TTM)22.46%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%29.55%

3.2 Future

HALO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.06% yearly.
HALO is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.27% yearly.
EPS Next Y24.79%
EPS Next 2Y26.9%
EPS Next 3Y24.66%
EPS Next 5Y16.06%
Revenue Next Year19.16%
Revenue Next 2Y21.57%
Revenue Next 3Y19.3%
Revenue Next 5Y11.27%

3.3 Evolution

The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
HALO Yearly Revenue VS EstimatesHALO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
HALO Yearly EPS VS EstimatesHALO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 4 6 8

More info and screens

9

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 13.90, HALO is valued correctly.
Based on the Price/Earnings ratio, HALO is valued cheaper than 97.01% of the companies in the same industry.
When comparing the Price/Earnings ratio of HALO to the average of the S&P500 Index (28.29), we can say HALO is valued rather cheaply.
The Price/Forward Earnings ratio is 11.14, which indicates a very decent valuation of HALO.
Based on the Price/Forward Earnings ratio, HALO is valued cheaply inside the industry as 96.48% of the companies are valued more expensively.
HALO's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 21.08.
Industry RankSector Rank
PE 13.9
Fwd PE 11.14
HALO Price Earnings VS Forward Price EarningsHALO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, HALO is valued cheaply inside the industry as 96.13% of the companies are valued more expensively.
96.30% of the companies in the same industry are more expensive than HALO, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 15.51
EV/EBITDA 12.16
HALO Per share dataHALO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

HALO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of HALO may justify a higher PE ratio.
HALO's earnings are expected to grow with 24.66% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.56
PEG (5Y)N/A
EPS Next 2Y26.9%
EPS Next 3Y24.66%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HALO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HALOZYME THERAPEUTICS INC

NASDAQ:HALO (4/17/2025, 8:26:03 PM)

After market: 59 +0.21 (+0.36%)

58.79

-0.03 (-0.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-18 2025-02-18/amc
Earnings (Next)05-13 2025-05-13/amc
Inst Owners99.23%
Inst Owner Change0%
Ins Owners0.81%
Ins Owner Change0.77%
Market Cap7.26B
Analysts77.33
Price Target69.11 (17.55%)
Short Float %8.04%
Short Ratio7.39
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.72%
Min EPS beat(2)6.64%
Max EPS beat(2)26.79%
EPS beat(4)4
Avg EPS beat(4)15.64%
Min EPS beat(4)6.64%
Max EPS beat(4)26.79%
EPS beat(8)6
Avg EPS beat(8)9.48%
EPS beat(12)9
Avg EPS beat(12)9.66%
EPS beat(16)13
Avg EPS beat(16)12.34%
Revenue beat(2)2
Avg Revenue beat(2)7.32%
Min Revenue beat(2)1.36%
Max Revenue beat(2)13.28%
Revenue beat(4)3
Avg Revenue beat(4)5.36%
Min Revenue beat(4)-3.87%
Max Revenue beat(4)13.28%
Revenue beat(8)4
Avg Revenue beat(8)2%
Revenue beat(12)6
Avg Revenue beat(12)1.1%
Revenue beat(16)9
Avg Revenue beat(16)3.23%
PT rev (1m)2.48%
PT rev (3m)5.65%
EPS NQ rev (1m)1.44%
EPS NQ rev (3m)-9.94%
EPS NY rev (1m)5.59%
EPS NY rev (3m)6.05%
Revenue NQ rev (1m)0.38%
Revenue NQ rev (3m)-10.67%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.39%
Valuation
Industry RankSector Rank
PE 13.9
Fwd PE 11.14
P/S 7.15
P/FCF 15.51
P/OCF 15.16
P/B 19.96
P/tB N/A
EV/EBITDA 12.16
EPS(TTM)4.23
EY7.2%
EPS(NY)5.28
Fwd EY8.98%
FCF(TTM)3.79
FCFY6.45%
OCF(TTM)3.88
OCFY6.6%
SpS8.22
BVpS2.95
TBVpS-3.68
PEG (NY)0.56
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 21.52%
ROE 122.06%
ROCE 28.66%
ROIC 23%
ROICexc 33.33%
ROICexgc 86.86%
OM 54.32%
PM (TTM) 43.74%
GM 84.3%
FCFM 46.13%
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
ROICexc(3y)23.94%
ROICexc(5y)N/A
ROICexgc(3y)71.73%
ROICexgc(5y)N/A
ROCE(3y)22.19%
ROCE(5y)37.11%
ROICexcg growth 3Y-1.13%
ROICexcg growth 5YN/A
ROICexc growth 3Y-28.16%
ROICexc growth 5YN/A
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
F-Score9
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 4.14
Debt/FCF 3.21
Debt/EBITDA 2.38
Cap/Depr 13.15%
Cap/Sales 1.05%
Interest Coverage 52.2
Cash Conversion 75.71%
Profit Quality 105.47%
Current Ratio 7.8
Quick Ratio 6.78
Altman-Z 4.73
F-Score9
WACC9.48%
ROIC/WACC2.43
Cap/Depr(3y)13.62%
Cap/Depr(5y)33.32%
Cap/Sales(3y)1.21%
Cap/Sales(5y)0.98%
Profit Quality(3y)118.15%
Profit Quality(5y)93.9%
High Growth Momentum
Growth
EPS 1Y (TTM)52.16%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%53.66%
EPS Next Y24.79%
EPS Next 2Y26.9%
EPS Next 3Y24.66%
EPS Next 5Y16.06%
Revenue 1Y (TTM)22.46%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%29.55%
Revenue Next Year19.16%
Revenue Next 2Y21.57%
Revenue Next 3Y19.3%
Revenue Next 5Y11.27%
EBIT growth 1Y62.13%
EBIT growth 3Y25.97%
EBIT growth 5YN/A
EBIT Next Year42.78%
EBIT Next 3Y32.05%
EBIT Next 5Y15.57%
FCF growth 1Y25.47%
FCF growth 3Y16.28%
FCF growth 5YN/A
OCF growth 1Y23.29%
OCF growth 3Y16.96%
OCF growth 5YN/A